Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 2/20 | 0.35 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.35 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.35 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.35 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.35 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.35 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.35 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.35 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16321199 | 0.93 | SMN1; SMN2 (0.63) | SMN1; SMN2HTTCYP3A4CYP2B6HSD17B10 | |
| SCHEMBL16321200 | 0.93 | SMN1; SMN2 (0.63) | SMN1; SMN2HTTCYP3A4CYP2B6HSD17B10 | |
| SCHEMBL30998785 | 0.85 | SMN1; SMN2 (0.62) | SMN1; SMN2HTTCYP3A4CYP2B6HSD17B10 | |
| SCHEMBL16322793 | 0.84 | SMN1; SMN2 (0.71) | SMN1; SMN2HTTCYP3A4CYP2B6HSD17B10 | |
| SCHEMBL16322795 | 0.84 | SMN1; SMN2 (0.71) | SMN1; SMN2HTTCYP3A4CYP2B6HSD17B10 | |
| SCHEMBL16322521 | 0.79 | SMN1; SMN2 (0.63) | SMN1; SMN2HTTCYP3A4CYP2B6MEN1 | |
| SCHEMBL16322520 | 0.79 | SMN1; SMN2 (0.63) | SMN1; SMN2HTTCYP3A4CYP2B6MEN1 | |
| SCHEMBL16321210 | 0.78 | SMN1; SMN2 (0.62) | SMN1; SMN2HTTCYP3A4CYP2B6MAPT | |
| SCHEMBL16321211 | 0.78 | SMN1; SMN2 (0.62) | SMN1; SMN2HTTCYP3A4CYP2B6MAPT | |
| SCHEMBL16321726 | 0.76 | SMN1; SMN2 (0.59) | SMN1; SMN2HTTCYP3A4CYP2B6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338378-A1 | Methods of Administering Myosin Inhibitors | MyoKardia, Inc. | 2023-10-26 | — | — | US | disclosed |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230158027-A1 | METHODS OF TREATMENT WITH MYOSIN MODULATOR | MyoKardia, Inc. | 2023-05-25 | — | — | US | disclosed |
| US-20170281626-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-9585883-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160030428-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-9181200-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158027-A1 | METHODS OF TREATMENT WITH MYOSIN MODULATOR | MYH10, MYH2, MYH14 | SMN1; SMN2 134/4885HTT 222/4885CYP3A4 4368/4885 |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885 |
| US-20160030428-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885 |
| US-20170281626-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885 |
| US-20230338378-A1 | Methods of Administering Myosin Inhibitors | MYH2, MYLK2, MYH10 | SMN1; SMN2 283/4885HTT 1999/4885CYP3A4 3078/4885 |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.